Cost-effective isolation of Viburnum opulus-derived nanovesicles and evaluation of their cytotoxic, anticancer, and antioxidant properties on human glioblastoma cell line U87MG DOI Creative Commons
NAZLI IRMAK GİRİTLİOĞLU, Fatma Şayan Poyraz, Banu Mansuroğlu

и другие.

Medical Oncology, Год журнала: 2025, Номер 42(4)

Опубликована: Март 17, 2025

Abstract Glioblastoma is the most common and highly invasive glial tumor, significantly reducing patient survival. Current therapeutic approaches have limited success rates. Plant-derived nanovesicles are a rapidly developing area, recognized for their exceptional biofunctional properties, emerging as promising approach in cancer treatment. The present study focuses on isolation of from Viburnum opulus fruits using cost-effective method that includes polymer-based exosome precipitation buffer size exclusion chromatography, followed by characterization. Morphological analysis via Field Emission Scanning Electron Microscopy Transmission revealed ranging oval to elliptical shapes, with average diameters 54.23 nm 41.21 nm, respectively. Dynamic light scattering determined 45.36 indicating presence nanovesicles, zeta potential was − 2.87 mV. Biochemical characterization showed total protein phenolic concentrations 1534 ± 97.78 µg/ml 4.270 0.66 mg gallic acid equivalents/L, respectively, antioxidant status values 3.83 0.37 mmol Trolox equivalents/L. Based IC50 values, these were 7.5 times more toxic U87MG human glioblastoma cells compared healthy dermal fibroblasts. Analyses including clonogenic cell survival, wound healing, apoptosis, status, oxidant continued only cells, fibroblasts low response nanovesicle Qualitative quantitative assessments demonstrated -derived effectively inhibited proliferation migration. Due non-toxic, anticancer, hold significant management. Graphical abstract

Язык: Английский

Glioblastoma Therapy: Past, Present and Future DOI Open Access
Elena Obrador, Paz Moreno-Murciano, María Oriol‐Caballo

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(5), С. 2529 - 2529

Опубликована: Фев. 21, 2024

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer. Although great efforts have been made by clinicians researchers, no significant improvement in survival has achieved since Stupp protocol became standard care (SOC) 2005. Despite multimodality treatments, recurrence is almost universal with rates under 2 years after diagnosis. Here, we discuss recent progress our understanding GB pathophysiology, particular, importance glioma stem cells (GSCs), tumor microenvironment conditions, epigenetic mechanisms involved growth, aggressiveness recurrence. The discussion on therapeutic strategies first covers SOC treatment targeted therapies that shown to interfere different signaling pathways (pRB/CDK4/RB1/P16

Язык: Английский

Процитировано

63
Targeted Glioma Therapy—Clinical Trials and Future Directions DOI Creative Commons
A. B. Shikalov, Igor Koman, Natalya M. Kogan

и другие.

Pharmaceutics, Год журнала: 2024, Номер 16(1), С. 100 - 100

Опубликована: Янв. 11, 2024

Glioblastoma multiforme (GBM) is the most common type of glioma, with a median survival 14.6 months post-diagnosis. Understanding molecular profile such tumors allowed development specific targeted therapies toward GBM, major role attributed to tyrosine kinase receptor inhibitors and immune checkpoint inhibitors. Targeted therapeutics are drugs that work by binding GBM-specific or overexpressed markers on tumor cellular surface therefore contain recognition moiety linked cytotoxic agent, which produces an antiproliferative effect. In this review, we have summarized available information used in clinical trials GBM current obstacles advances therapy concerning targets present cells, outlined efficacy endpoints for classes investigational drugs, discussed promising strategies towards increase drug GBM.

Язык: Английский

Процитировано

12
Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments DOI Creative Commons
Lisa Feldman

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Июнь 26, 2024

Glioblastoma (GBM) tumors are the most aggressive primary brain in adults that, despite maximum treatment, carry a dismal prognosis. GBM exhibit tissue hypoxia, which promotes tumor aggressiveness and maintenance of glioma stem cells creates an overall immunosuppressive landscape. This article reviews how hypoxic conditions overlap with inflammatory responses, favoring proliferation inhibiting cytotoxic T cell development. Immunotherapies, including vaccines, immune checkpoint inhibitors, CAR-T therapy, represent promising avenues for treatment. However, challenges such as heterogeneity, TME, BBB restrictiveness hinder their effectiveness. Strategies to address these challenges, combination therapies targeting actively being explored improve outcomes patients. Targeting hypoxia immunotherapy represents potential strategy enhance treatment efficacy.

Язык: Английский

Процитировано

11
Components, Formulations, Deliveries, and Combinations of Tumor Vaccines DOI
Tengfei Liu,

Wenyan Yao,

Wenyu Sun

и другие.

ACS Nano, Год журнала: 2024, Номер 18(29), С. 18801 - 18833

Опубликована: Июль 9, 2024

Tumor vaccines, an important part of immunotherapy, prevent cancer or kill existing tumor cells by activating restoring the body's own immune system. Currently, various formulations vaccines have been developed, including cell membrane DNA mRNA polypeptide virus-vectored and tumor-in-situ vaccines. There are also multiple delivery systems for such as liposomes, vesicles, viruses, exosomes, emulsions. In addition, to decrease risk escape tolerance that may exist with a single vaccine, combination therapy radiotherapy, chemotherapy, checkpoint inhibitors, cytokines, CAR-T therapy, photoimmunotherapy is effective strategy. Given critical role in here, we look back history discuss antigens, adjuvants, formulations, systems, mechanisms, future directions

Язык: Английский

Процитировано

10
A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives DOI
Giacomo Sferruzza, Stefano Consoli, Fedele Dono

и другие.

Neurological Sciences, Год журнала: 2024, Номер 45(6), С. 2561 - 2578

Опубликована: Фев. 3, 2024

Язык: Английский

Процитировано

9
Oncolytic viral therapy for gliomas: Advances in the mechanisms and approaches to delivery DOI
Alexander Romanishin,

A. Yu. Vasil’ev,

E Khasanshin

и другие.

Virology, Год журнала: 2024, Номер 593, С. 110033 - 110033

Опубликована: Фев. 20, 2024

Язык: Английский

Процитировано

8
Emerging Therapies for Glioblastoma DOI Open Access
Stella Rios,

Stephanie Oyervides,

David Uribe

и другие.

Cancers, Год журнала: 2024, Номер 16(8), С. 1485 - 1485

Опубликована: Апрель 12, 2024

Glioblastoma is most commonly a primary brain tumor and the utmost malignant one, with survival rate of approximately 12–18 months. highly heterogeneous, demonstrating that different types cells from same can manifest distinct gene expression patterns biological behaviors. Conventional therapies such as temozolomide, radiation, surgery have limitations. As now, there no cure for glioblastoma. Alternative treatment methods to eradicate glioblastoma are discussed in this review, including targeted PI3K, NFKβ, JAK-STAT, CK2, WNT, NOTCH, Hedgehog, TGFβ pathways. The novel application oncolytic viruses nanomaterials combating also discussed. Despite scores clinical trials glioblastoma, prognosis remains poor. Progress breaching blood–brain barrier avenues combination treatments hold promise future development efficacious therapies.

Язык: Английский

Процитировано

8
Viruses in glioblastoma: an update on evidence and clinical trials DOI Creative Commons
Bavani Gunasegaran, Caroline L. Ashley, Felix Marsh‐Wakefield

и другие.

BJC Reports, Год журнала: 2024, Номер 2(1)

Опубликована: Апрель 19, 2024

Glioblastoma (GB) is a lethal and aggressive brain tumour. While molecular characteristics of GB studied extensively, the aetiology remains uncertain. The interest in exploring viruses as potential contributor to development stems from notion that are known play key role pathogenesis other human cancers such cervical cancer. Nevertheless, controversial.

Язык: Английский

Процитировано

8
Deciphering the roles of aryl hydrocarbon receptor (AHR) in regulating carcinogenesis DOI Creative Commons
Zhi Xiong Chong, Chean Yeah Yong, Han Kiat Ong

и другие.

Toxicology, Год журнала: 2023, Номер 495, С. 153596 - 153596

Опубликована: Июль 20, 2023

Aryl hydrocarbon receptor (AHR) is a ligand-dependent that belongs to the superfamily of basic helix-loop-helix (bHLH) transcription factors. The activation canonical AHR signaling pathway known induce expression cytochrome P450 enzymes, facilitating detoxification metabolism in human body. Additionally, could interact with various pathways such as epidermal growth factor (EGFR), signal transducer and activator 3 (STAT3), hypoxia-inducible factor-1α (HIF-1α), nuclear kappa B (NF-κβ), estrogen (ER), androgen (AR) pathways. Over past 30 years, several studies have reported chemical, physical, or biological agents, tobacco, compounds, industrial agricultural chemical wastes, drugs, UV, viruses, other toxins, affect activity, promoting cancer development. Thus, it valuable overview how these factors regulate AHR-mediated carcinogenesis. Current findings many compounds act ligands drive expressions AHR-target genes, CYP1A1, CYP1B1, MMPs, AXL, targets exert pro-proliferation anti-apoptotic effect, like XIAP. Furthermore, some physical UV 3-methylcholanthrene, promote activities, increasing activities few oncogenic pathways, phosphatidylinositol 3-kinase/protein kinase (PI3K/AKT) mitogen-activated protein kinase/extracellular signal-regulated (MAPK/ERK) Understanding carcinogenesis processes helps clinicians scientists plan personalized therapeutic strategies improve anti-cancer treatment efficacy. As roles regulating are preclinical observational clinical did not explore detailed mechanisms different agents processes, future should focus on conducting large-scale functional unravel underlying mechanism interacts processes.

Язык: Английский

Процитировано

17
Glioma–Immune Cell Crosstalk in Tumor Progression DOI Open Access
Mahmoud Elguindy, Jacob S. Young, Isha Mondal

и другие.

Cancers, Год журнала: 2024, Номер 16(2), С. 308 - 308

Опубликована: Янв. 11, 2024

Glioma progression is a complex process controlled by molecular factors that coordinate the crosstalk between tumor cells and components of microenvironment (TME). Among these, immune play critical role in cancer survival progression. The interplay TME influences outcome immunotherapy other anti-cancer therapies. Here, we present an updated view pro- anti-tumor activities main myeloid lymphocyte cell populations glioma TME. We review underlying mechanisms involved enable gliomas to evade system co-opt these for growth. Lastly, discuss current experimental therapeutic options being developed revert immunosuppressive activity Knowledge elapses may help develop new combination treatments able overcome evasion enhance response immunotherapies.

Язык: Английский

Процитировано

8